QUANTUM X LABS INC. quarterly report, Q3 FY2021

Viewbix Inc. — Form 10-Q Summary

Entity note: The request identifies Quantum X Labs Inc., but the supplied filing is for Viewbix Inc. (formerly Virtual Crypto Technologies, Inc.), ticker VBIX. Confirm the filing and issuer match the intended company.

Business context and reporting period

This unaudited quarterly report covers the three and nine months ended September 30, 2021, with comparisons to the corresponding 2020 periods. Viewbix describes its business as an interactive video technology and data platform for video marketing. Financial amounts below are in U.S. dollars in thousands unless stated otherwise.

Financial results and liquidity

MetricThree months ended Sep. 30, 2021Three months ended Sep. 30, 2020Nine months ended Sep. 30, 2021Nine months ended Sep. 30, 2020
Revenue$7$17$32$86
Gross profit$7$16$32$81
Operating loss$91$55$238$317
Net loss$97$44$256$311
Basic and diluted loss per share$0.003$0.001$0.007$0.01
Operating cash flow$(24)$(14)$(46)$(37)

Gross margin was approximately 100% in the 2021 periods, compared with approximately 94% for the 2020 nine-month period and 94% for the 2020 quarter, based on reported revenue and cost of revenue. The company had no reported cost of revenue in 2021.

At September 30, 2021, cash was $102, current assets were $180, current liabilities were $2,514, and working capital was negative $2,334. Current liabilities included $2,226 payable to the parent company, a $64 short-term loan, $219 in other payables and accrued liabilities, and $5 in trade payables. The balance sheet reports a stockholders’ deficit of $2,334. Cash decreased by $46 during the first nine months of 2021; investing cash flow was zero.

Material changes versus prior periods

  • Nine-month revenue fell to $32 from $86; management attributed the decline to cost-reduction measures begun in January 2020 after revenue targets were missed.
  • Nine-month net loss improved to $256 from $311, primarily alongside lower research and development and general and administrative expenses. However, nine-month operating cash use increased to $46 from $37.
  • For the third quarter, revenue declined to $7 from $17 and net loss increased to $97 from $44. Management cited R&D team costs, legal fees, and a shift from net financial income to net financial expense.
  • Cash fell from $148 at December 31, 2020, to $102 at September 30, 2021. Amounts payable to the parent company rose from $2,054 to $2,226.

Outlook, risks, contingencies, and unusual items

  • Going concern: Management states that substantial operating losses are expected to continue and that the company expects to rely on existing resources and additional capital raises. The filing says these conditions raise substantial doubt about the company’s ability to continue as a going concern; outside funding is not assured.
  • Funding and dilution: The company has no committed external funding source. It may seek equity, convertible debt, debt financing, or strategic arrangements; financing may be unavailable, costly, dilutive, or restrictive. Failure to obtain funding could require reducing or terminating operations.
  • Other stated risks: Insufficient capital and difficulty retaining customers, management turnover, COVID-19 impacts, intellectual-property protection, competition, and possible technological obsolescence.
  • COVID-19: Management says the full effect on the business and financial condition cannot be estimated.
  • Legal matter: A former CEO’s wrongful-termination claim sought approximately $225. The filing reports that the case against Emerald Israel was dismissed on June 3, 2021. Verify whether any claims against other defendants remain relevant.
  • Controls: Management concluded disclosure controls were ineffective due to material weaknesses. The text describes the evaluation as being as of September 30, 2020, despite the report being for the quarter ended September 30, 2021; verify the intended date.
  • Potential dilution: 7,298,636 Class J and K warrants were outstanding and exercisable, with exercise prices of $0.48 and $0.80, respectively. The filing also describes a potential additional issuance of 1,642,193 shares to Gix upon specified product launches.
  • Guidance: The filing provides no quantified revenue, earnings, or cash-flow guidance.

Important facts for investors to verify

  • Confirm that Viewbix Inc. (VBIX), rather than Quantum X Labs Inc., is the intended issuer.
  • Assess the company’s ability to fund operations given $102 of cash, negative $2,334 working capital, and the going-concern warning.
  • Clarify repayment terms and timing for the $2,226 parent-company payable and the short-term loan.
  • Check the disclosure-controls evaluation date and the status of any claims not covered by the reported dismissal.
  • Reconcile internal presentation inconsistencies: the filing’s third-quarter loss-before-tax figures differ between sections, and its working-capital discussion labels a figure equal to the stockholders’ deficit.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.